Myocardial Perfusion Imaging Galmydar Rest/Stress

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging

A single center, phase 0/1 clinical imaging study designed to assess the role of [68Ga]Galmydar PET/CT imaging in human subjects.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Drug: Ga-68 Galmydar; Drug: 13N-ammonia

Detailed Description

The primary objective of the proposed study is to evaluate the potential of [68Ga]Galmydar PET/CT myocardial perfusion imaging (MPI) for the noninvasive detection of coronary artery disease. The study will evaluate [68Ga]Galmydar PET/CT MPI to semi-quantitatively assess regional myocardial perfusion and quantitatively assess myocardial blood flow (MBF) in patients with suspected or known coronary artery disease (CAD) undergoing clinical SPECT or PET MPI. In addition, perfusion and MBF findings with [68Ga]Galmydar will be compared to the results of coronary morphology or stenosis severity in those patients undergoing invasive coronary angiography (ICA) based on abnormal clinical SPECT or PET MPI. The performance of rest/stress [68Ga]Galmydar PET/CT in comparison to [13N]ammonia PET/CT in normal subjects without cardiovascular disease will be performed as a control. Vital signs, serum chemistries, and serum blood counts will also be obtained.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 95 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male and female, 18-99 years of age and any race;
• Have had a prior clinical SPECT or PET MPI positive for ischemia in two myocardial segments and referred for invasive coronary angiography (ICA) or have had a prior clinical SPECT or PET MPI negative for ischemia or healthy adult normal volunteers who are asymptomatic, without history of cardiovascular disease or significant cardiovascular risk factors;

Exclusion Criteria:

• Inability to receive and sign informed consent;
• Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6-months prior to clinical SPECT or PET or in the intervening days between clinical SPECT or PET and research PET examination;
• Participants who have received chemotherapeutic agents within 6 months of enrollment;
• Heart failure (left ventricular ejection fraction ≤ 20%);
• Known non-ischemic cardiomyopathy;

• Inability to undergo pharmacologic stress testing with regadenoson (Lexiscan). Contraindications include:

  • Symptomatic bradycardia or second to third degree atrioventricular (AV) block;
  • Pre-existing obstructive lung disease with active wheezing, i.e., COPD, asthma with active wheezing that precludes the safe administration of the pharmacological stress agent according to the approved label;
  • Uncontrolled and severe hypertension (e.g. systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg);
  • Baseline hypotension (e.g. systolic blood pressure < 90 mmHg, diastolic blood pressure <50 mmHg);
• Women who are pregnant or breastfeeding;
• Severe claustrophobia;
• Weight ≥ 500 lbs (weight limit of PET/CT table);
• Administration of any diagnostic or therapeutic radiopharmaceutical, not part of this study, within a period either prior to or after equal to 10 half-lives of the radiopharmaceutical;

• Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:

  • Inability to lie still or unable to tolerate a supine position with arms up over the head for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history;
  • Current or past history of major medical illness, i.e. severe kidney or liver problems;
  • Patients who suffer an intervening clinical event such as worsening angina pectoris or myocardial infarction or whom undergo a myocardial revascularization procedure or have myocardial ischemia at rest;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Asymptomatic Subjects (Normal Controls); Normal control subjects are asymptomatic, without history of cardiovascular disease or significant cardiovascular risk factors. These participants will receive two [68Ga]Galmydar intravenous administrations, 2 mCi during rest and 4 mCi during stress for the [68Ga]Galmydar PET MPI performed on Imaging Day-1. On Imaging Day-2, asymptomatic subjects will receive two single intravenous administrations each of 10 mCi of [13N]Ammonia during the rest and stress PET MPI. [68Ga]Galmydar and [13N]Ammonia imaging visits will be separated by a minimum of 3 days.	Drug: Ga-68 Galmydar; Intravenous injections of the PET radiotracer [68Ga]Galmydar.; Other Names: IND 157468; Drug: 13N-ammonia; Two intravenous injections of PET radiotracer [13N]Ammonia.
Experimental: Symptomatic Patients with Normal Clinical SPECT or PET; Patients in this group have had a clinical SPECT or PET MPI examination that is normal and do not have an invasive coronary angiography (ICA) referral. Participants will receive one [68Ga]Galmydar intravenous administration, 2 mCi during rest for the [68Ga]Galmydar PET MPI.	Drug: Ga-68 Galmydar; Intravenous injections of the PET radiotracer [68Ga]Galmydar.; Other Names: IND 157468
Experimental: Symptomatic Patients with Abnormal Clinical SPECT or PET; Patients in this group have had a clinical SPECT or PET MPI examination that is positive for ischemia in two myocardial segments and have been referred for invasive coronary angiography (ICA) as part of their routine standard-of-care. Subjects will undergo [68Ga]Galmydar PET/CT prior to any intervention. Participants will receive one [68Ga]Galmydar intravenous administration, 2 mCi during rest.	Drug: Ga-68 Galmydar; Intravenous injections of the PET radiotracer [68Ga]Galmydar.; Other Names: IND 157468

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Semiquantitative assessment of 68Ga-Galmydar PET/CT uptake	Assessment of regional (17segment) myocardial uptake on 5-point scale (0 = normal; 4 = absent tracer uptake) per independent blind readout by 3 expert cardiac PET physicians.	Up to 120 minutes post-injection of 68Ga-Galmydar

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinically significant change in respiratory rate.	A respiratory rate of < 12 or > 20 breaths/min.	6 hours from 68Ga-Galmydar injection
Clinically significant elevation in oral temperature	Oral temperature of >100 degrees F.	6 hours from 68Ga-Galmydar injection
Clinically significant change in serum chemistries: sodium, potassium, chloride, CO2	Serum chemistries (sodium, potassium, chloride, CO2) measured in mmol/L. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in serum chemistries: glucose, calcium creatinine, BUN, total bilirubin	Serum chemistries (glucose, calcium creatinine, BUN, total bilirubin), measured in mg/dL. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in serum chemistries: total protein, albumin.	Serum chemistries (total protein, albumin), measured in g/dL. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in white blood cell count (WBC)	White blood cell count measured in WBC/mm3 blood. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in hemoglobin (Hgb)	Hgb measured in g/dL. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in hematocrit (Hct)	Hct measured in %. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in platelets	Platelets measured in platelets/mm3 blood. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in red blood cell count (RBC)	RBC measured in million/mm3. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Clinically significant change in mean corpuscular volume (MCV)	MCV measured in µm3. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection
Change in systolic or diastolic blood pressure.	A 20 mmHg change from baseline in either systolic or diastolic blood pressure.	6 hours from 68Ga-Galmydar injection
Change in heart rate.	A 20 BPM change in heart rate from baseline.	6 hours from 68Ga-Galmydar injection
Number of patients with new bradycardia	New heart rate < 40 BPM on EKG.	6 hours from 68Ga-Galmydar injection
Assessment of myocardial blood flow on 68Ga-Galmydar PET/CT	Assessment of regional (17segment) myocardial blood flow (MBF) at stress and rest perfusion on 68Ga-Galmydar PET/CT.	Up to 120 minutes post-injection of 68Ga-Galmydar
Number of patients with new AV Block	A change in EKG showing new AV Block (Type 1 or Type 2), Mobitz 2:1, or QTc ≥ 500ms.	6 hours from 68Ga-Galmydar injection
Clinically significant change in serum chemistries: alkaline phosphatase, ALT, AST	Serum chemistries (alkaline phosphatase, ALT, AST), measured in U/L. Values outside of laboratory range in comparison to baseline or >20% difference from baseline values.	6 hours from 68Ga-Galmydar injection

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
• Investigators: Principal Investigator: Pamela K Woodard, M.D, Washington University School of Medicine

Publications and helpful links

General Publications

• Sivapackiam J, Laforest R, Sharma V. 68Ga[Ga]-Galmydar: Biodistribution and radiation dosimetry studies in rodents. Nucl Med Biol. 2018 Apr;59:29-35. doi: 10.1016/j.nucmedbio.2017.11.008. Epub 2017 Dec 1.

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2022
• Primary Completion (Actual): December 17, 2025
• Study Completion (Actual): December 19, 2025

Study Registration Dates

• First Submitted: November 13, 2022
• First Submitted That Met QC Criteria: November 20, 2022
• First Posted (Actual): November 23, 2022

Study Record Updates

• Last Update Posted (Estimated): January 7, 2026
• Last Update Submitted That Met QC Criteria: January 5, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Positron Emission Tomography; Myocardial Blood Flow; Myocardial Perfusion imaging; Pharmacological Stress
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Myocardial Ischemia; Coronary Artery Disease
• Other Study ID Numbers: 202107042-2; R01HL142297 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No